The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
BIGBONE"All the best for the future "
Surely dual indices is better than one . Tighter regulations U.S.A so initial cost but would that not help .
I've invested here as Cancer has not been kind to my family my 8yr old son been diagnosed with a very rare type of tumour PET scan next then hope successful removal . All the best all invested.
Main market not AIM. But valid concerns regarding LSE Market in its current state
The most worrying aspect of the Chairman's statement for me was the following para which has heightened my recent concerns. I have been very conscious of what has taken place at Redx and others - delisting from AIM and, more specifically, doing so off the back of the market failing to recognise their very strong positions (including having done some very big deals and with much cash in the bank); If more advanced companies such as those do not see the point of being on AIM then where does that leave Hemo on the future fund-raising front? Contrary and sensible arguments only by way of replies, please:
"While we accept that recent market conditions have been very difficult, we have been disappointed by the successively lower price at which we have had to carry out our fundraisings in the UK market, in the light of the progress we have made and the view taken by Prevail Partners concerning our status. The capital recently raised will undoubtedly take us materially further forward and we are now looking at a number of strategies for the future development of all three of our current product candidates."
Prof Sir Marc Feldmann AC, FRS
MB BS, PhD, FRCP, FRCPath, FAA, F Med Sci
Chairman
A chimeric goose-pheonix
The sunken goose will rise out of ashes a phoenix
Hemo have The golden goose but are stuck in sinking sand, the more they move forward the more the goose is submerged. I wonder how much we will have left when we make it to the end. I'm sure a few ropes have been chucked our way but not wanting to take either hand off the goose may end up costing us more.
Thank you Lostapound found a penny.
Simon
No. An initial patient. The first one injected in the next few months is their aim.
Cash in bank at end dec £1.247m and trade and other receivable £0.9m
The rns reads that they are only doing the trial on one candidate. Am I right or wrong on that?
Also not clear on exactly how much CAB was remaining at 31/12/23.
It’s important to know what the cash runway position looks like, how long have we got?
Where is the news on the trials we were promised within months from Feb 2024? That is the only thing people are waiting for and guess what, no update on that.
Morning all invested
RNS - does what it says on the tin
Not a stock mover .
Highlights the science continues development -
CAR T clinical
Underpinned by Prevail
Cash in the bank
CBR & CDX plenty of info on these developments & huge potential
Let’s see what next few months bring - I’m sure Vlad & Prevail aren’t sat twiddling their thumbs
All invested have choices - buy - hold - sell
I’m very content to let all Hemo science unfold & stock re rate - especially from current levels
Dry powder level imo the science is developing & a nice juicy pharma deal would suffice .
Looks and sounds to me the most important part the science is coming along and vlad is now in a position where he can spare some time on the website and rns to me the end goal is nearing all the boxes and hurdles are being ticked not long to go until life’s are being saved in my opinion
Hi ,
do you have link to the SCAP update please?
thanks
You are correct with your assumption at £550k pcm burn rate.
Having read the statement twice I still can’t see what the CAB figure is at 31/12/23, have I missed it somewhere?
Trying to establish the remaining cash runway
Does anybody else think that the statement below suggests that they're looking to move the listing to the US market ?
"While we accept that recent market conditions have been very difficult, we have been disappointed by the successively lower price at which we have had to carry out our fundraisings in the UK market, in the light of the progress we have made and the view taken by Prevail Partners concerning our status. The capital recently raised will undoubtedly take us materially further forward and we are now looking at a number of strategies for the future development of all three of our current product candidates."
Thanks 1902 I wasn’t sure
Its potential ability as an Alzheimer's treatment is not new. It was revealed last year I think.
My guess would be dec balance + raise - cash burn since jan.
Is point 5. The potential to be able to treat Alzheimer’s new info as I don’t remember reading.
It's such a shame that companies like this aren't supported by the government.Especially when you consider the billions spunked out on covid.Imagine if you spend billions on research instead of the appalling waste of public money by an inept corrupt government
Ok"what is the cash position now?
An excellent update on the science from Hemo today. i.e. HEMO-CAR-T progressing well as we all know and expect with the commencement via injection in the coming months but the real eye opener is the progress being made by Hemo's CBR. This also looks very promising:
1. Testing the efficacy of CBR-COVID19 against live infectious replicating SARS-CoV-2 virus in a major Biosafety Level 3 facility.
2. CBR can also be adapted to target several solid tumours such as epithelial ovarian cancer.
3. NHL is the eleventh most common cancer in humans, with a poor rate of recovery and cure from present treatments. There are currently an estimated 540,000 new cases diagnosed globally with an estimated 260,000 deaths per year.
4. CBRs can be adapted to target several solid tumours such as epithelial ovarian cancer.
5. Evidence that a CBR-based approach may also potentially be effective against certain neurodegenerative diseases, some of which are currently very difficult or impossible to treat, including possibly Alzheimer's disease.
6. Hemo briefing that CBR could potentially find and destroy brain cancer cells.
In summary, there's big news developing on the CBR front as well as with HEMO-CAR-T. The potential value of this small company is increasing by the day.